Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | IDE | P14735 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18040317 | 0.85 | MAPT (0.37) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL18040314 | 0.85 | MAPT (0.37) | MAPTKDM4EGAABLMAKR1C3 | |
| SCHEMBL17205575 | 0.85 | SIRT6 (0.61) | MAPTALDH1A1HPGDSIRT6POLB | |
| SCHEMBL15731795 | 0.82 | PIK3R1 (0.39) | MAPTKDM4EGAAALDH1A1KMT2A | |
| SCHEMBL1919863 | 0.81 | AKR1C3 (0.44) | MAPTBLMAKR1C3ALDH1A1CYP1A2 | |
| SCHEMBL6330031 | 0.81 | KMT2A (0.49) | MAPTKDM4EAKR1C3ALDH1A1KMT2A | |
| SCHEMBL17576245 | 0.81 | AKR1C3 (0.44) | MAPTKDM4EGAAAKR1C3ALDH1A1 | |
| SCHEMBL29483984 | 0.81 | RAD51 (0.51) | MAPTAKR1C3KMT2ATDP1MEN1 | |
| SCHEMBL20050092 | 0.81 | ALDH1A1 (0.42) | MAPTKDM4EGAAALDH1A1CYP1A2 | |
| SCHEMBL16730298 | 0.81 | MAPT (0.51) | MAPTKDM4EALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552160-A | Preparation method of apixaban | 济南健丰化工有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-117926290-A | Preparation method of apixaban intermediate | 成都化润药业有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117659011-A | New method for synthesizing apixaban | 华东理工大学 | 2024-03-08 | — | — | CN | claimed |
| EP-3212620-B1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LTD FORMERLY JUBILANT LIFE SCIENCES DIVISION (IN) | 2020-11-25 | — | — | EP | claimed |
| WO-2018158620-A1 | PREPARATION OF ACTIVE PHARMACEUTICAL INGREDIENTS AND INTERMEDIATES THEREOF | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2018-09-07 | — | — | WO | claimed |
| US-9932336-B2 | Process for the preparation of apixaban and intermediates thereof | Jubilant Generics Limited (IN) | 2018-04-03 | — | — | US | claimed |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (IN) | 2017-11-02 | — | — | US | claimed |
| EP-3212620-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) (IN) | 2017-09-06 | — | — | EP | claimed |
| US-9603846-B2 | Process for the preparation of apixaban | CADILA HEALTHCARE LIMITED (IN) | 2017-03-28 | — | — | US | claimed |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CADILA HEALTHCARE LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| WO-2016067308-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | JUBILANT GENERICS LIMITED (FORMERLY JUBILANT LIFE SCIENCES DIVISION) (IN) | 2016-05-06 | — | — | WO | claimed |
| US-20160113912-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2016-04-28 | — | — | US | claimed |
| WO-2014203275-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| CN-119552160-A | Preparation method of apixaban | 济南健丰化工有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117926290-A | Preparation method of apixaban intermediate | 成都化润药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117926290-A | Preparation method of apixaban intermediate | 成都化润药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-09 | — | — | US | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232804-A1 | Glycinamides as factor Xa inhibitors | F11, F13B, F12 | MAPT 4222/4885KDM4E 2789/4885GAA 107/4885 |
| US-20040220174-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, PRSS1, CPB1 | MAPT 4597/4885KDM4E 1548/4885GAA 898/4885 |
| US-20160143894-A1 | PROCESS FOR THE PREPARATION OF APIXABAN | CYP4X1, CYP4B1, NPPA | MAPT 4422/4885KDM4E 1186/4885GAA 2812/4885 |
| US-20160113912-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, F12 | MAPT 3949/4885KDM4E 3065/4885GAA 428/4885 |
| US-20030191115-A1 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | PEPD, HABP2, CPB1 | MAPT 4569/4885KDM4E 3252/4885GAA 466/4885 |
| US-20170313699-A1 | PROCESS FOR THE PREPARATION OF APIXABAN AND INTERMEDIATES THEREOF | VKORC1, VKORC1L1, CYP4X1 | MAPT 4806/4885KDM4E 2146/4885GAA 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.